Journey Medical reports FY25 EPS (47c) vs. (72c) last year

Reports FY25 revenue $61.9M, consensus $64.7M. Claude Maraoui, CEO, said, “We delivered a year of meaningful commercial progress, highlighted by the successful launch and rapid uptake of Emrosi(TM), which is driving solid revenue growth and expanding our presence in medical dermatology. Our financial performance continues to strengthen with rising net product revenues, improving gross margins and expense optimization, supported by disciplined investment in our dermatology focused sales infrastructure. Emrosi(TM) achieved strong prescription momentum and broader payer access throughout the year, and its differentiated clinical profile further reinforces our confidence in the product’s long-term potential as a key growth driver for our Company. As we look ahead to 2026 and beyond, we remain well-positioned to continue to execute on our strategy, leveraging our commercial platform to drive improving financial performance, and advancing innovative therapies that address important needs for patients with dermatologic conditions, while increasing value for our shareholders.”